Table 1.
Patient characteristics of the 154 patients selected from the ABCSG-34 trial
| CON (n = 76) | REV (n = 78) | Total (n = 154) | |
|---|---|---|---|
| Age (years) | |||
| Median (min–max) | 48 (26–78) | 47 (26–75) | 47 (26–78) |
| BMI | |||
| Median (min–max) | 25 (18–35) | 25 (19–41) | 25 (18–41) |
| Menopausal status – n (%) | |||
| Perimenopausal | 29 (38.2%) | 28 (35.9%) | 57 (37.0%) |
| Postmenopausal | 3 (3.9%) | 3 (3.8%) | 6 (3.9%) |
| Premenopausal | 44 (57.9%) | 47 (60.3%) | 91 (59.1%) |
| T-stage – n (%) | |||
| T1 | 18 (23.7%) | 24 (30.8%) | 42 (27.3%) |
| T2/T3/T4 | 58 (76.3%) | 54 (69.2%) | 112 (72.7%) |
| Triple negative – n (%) | |||
| No | 41 (53.9%) | 47 (60.3%) | 88 (57.1%) |
| Yes | 27 (35.5%) | 27 (34.6%) | 54 (35.1%) |
| Missing | 8 (10.5%) | 4 (5.1%) | 12 (7.8%) |
| N-stage – n (%) | |||
| Negative | 41 (53.9%) | 39 (50.0%) | 80 (51.9%) |
| Positive | 33 (43.4%) | 39 (50.0%) | 72 (46.8%) |
| Missing | 2 (2.6%) | 0 (0.0%) | 2 (1.3%) |
| M-stage – n (%) | |||
| M0 | 76 (100.0%) | 78 (100.0%) | 154 (100.0%) |
| Grading – n (%) | |||
| G1 | 1 (1.3%) | 1 (1.3%) | 2 (1.3%) |
| G2/Gx | 23 (30.3%) | 23 (29.5%) | 46 (29.9%) |
| G3 | 49 (64.5%) | 52 (66.7%) | 101 (65.6%) |
| Missing | 3 (3.9%) | 2 (2.6%) | 5 (3.2%) |
| Her2 – n (%) | |||
| Negative | 64 (84.2%) | 67 (85.9%) | 131 (85.1%) |
| Positive | 0 (0.0%) | 1 (1.3%) | 1 (0.6%) |
| Missing | 12 (15.8%) | 10 (12.8%) | 22 (14.3%) |
| ER – n (%) | |||
| Negative | 37 (48.7%) | 35 (44.9%) | 72 (46.8%) |
| Positive | 36 (47.4%) | 42 (53.8%) | 78 (50.6%) |
| Missing | 3 (3.9%) | 1 (1.3%) | 4 (2.6%) |
| PgR – n (%) | |||
| Negative | 36 (47.4%) | 35 (44.9%) | 71 (46.1%) |
| Positive | 37 (48.7%) | 42 (53.8%) | 79 (51.3%) |
| Missing | 3 (3.9%) | 1 (1.3%) | 4 (2.6%) |
| Ki67 | |||
| N | 73.0 | 74.0 | 147 |
| Median (min–max) | 50 (3–90) | 50 (3–90) | 50 (3–90) |
| Surgery Type – n (%) | |||
| Breast conserving | 46 (60.5%) | 43 (55.1%) | 89 (57.8%) |
| Mastectomy | 21 (27.6%) | 24 (30.8%) | 45 (29.2%) |
| Other | 6 (7.9%) | 6 (7.7%) | 12 (7.8%) |
| Skin sparing mastectomy | 2 (2.6%) | 3 (3.8%) | 5 (3.2%) |
| Missing | 1 (1.3%) | 2 (2.6%) | 3 (1.9%) |
| Sentinel node biopsy – n (%) | |||
| No | 29 (38.2%) | 27 (34.6%) | 56 (36.4%) |
| Yes | 47 (61.8%) | 49 (62.8%) | 96 (62.3%) |
| Missing | 0 (0.0%) | 2 (2.6%) | 2 (1.3%) |
| Axilla dissection – n (%) | |||
| No | 33 (43.4%) | 29 (37.2%) | 62 (40.3%) |
| Yes | 43 (56.6%) | 47 (60.3%) | 90 (58.4%) |
| Missing | 0 (0.0%) | 2 (2.6%) | 2 (1.3%) |
| RCB – n (%) | |||
| RCB 0 | 16 (21.1%) | 15 (19.2%) | 31 (20.1%) |
| RCB I | 10 (13.2%) | 13 (16.7%) | 23 (14.9%) |
| RCB II | 34 (44.7%) | 30 (38.5%) | 64 (41.6%) |
| RCB III | 10 (13.2%) | 15 (19.2%) | 25 (16.2%) |
| Missing | 6 (7.9%) | 5 (6.4%) | 11 (7.1%) |
| pCR – n (%) | |||
| No | 58 (76.3%) | 59 (75.6%) | 117 (76.0%) |
| Yes | 17 (22.4%) | 16 (20.5%) | 33 (21.4%) |
| Missing | 1 (1.3%) | 3 (3.8%) | 4 (2.6%) |
N number of patients in ITT analysis set, CON conventional neoadjuvant chemotherapy scheme, REV reverse neoadjuvant chemotherapy scheme, SD standard deviation, Min Minimum, Max Maximum, BMI body mass index, Her2 human epidermal growth factor receptor 2, ER estrogen receptor, PgR progesterone receptor, RCB Residual Cancer Burden, pCR pathologic complete response. For patients who experience bilateral cancer information from the worse side is used for descriptive summaries